Sang‐Hoon Lee

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler et al. · The Lancet · 2019 · 208 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker

Sang‐Hoon Lee, Eun Jung Lee, Sang Wan Chung et al. · Rheumatology International · 2012 · 61 citations

Rheumatology, Urology, Autoimmune Disease +13

Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients

Sang‐Hoon Lee, Yeon-Ah Lee, Seung‐Jae Hong et al. · Clinical Rheumatology · 2007 · 37 citations

Rheumatology, Spondyloarthritis, Rheumatic Diseases +8

Green Nail Syndrome Treated with the Application of Tobramycin Eye Drop

Youin Bae, Gang Mo Lee, Ji‐Hoon Sim et al. · Annals of Dermatology · 2014 · 29 citations · Full text

Antibiotics, Ophthalmology, Tobramycin Eye Drop +7